Design, synthesis and immunological evaluation of monophosphoryl lipid A derivatives as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine-Reference-Cited by-同舟云学术

Design, synthesis and immunological evaluation of monophosphoryl lipid A derivatives as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine

Published:2023 Issue:1 Volume:14 Page:47-55
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Su Shiwei¹,Chen Liqing¹²,Yang Menglan¹,Liang Dan³,Ke Bixia³,Liu Zhongqiu¹,Ke Changwen³,Liao Guochao¹⁴^ORCID,Liu Liang²⁴⁵,Luo Xiang¹

Affiliation:

1. Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China

2. State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

3. Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China

4. Guangdong Hengda Biomedical Technology Co., Ltd., Guangzhou, China

5. Guangzhou Laboratory, Guangzhou, China

Abstract

MPLA derivatives are expected to be a promising platform for the development of new adjuvants used for a RBD-hFc based SARS-CoV-2 vaccine.

Funder

Guangdong Science and Technology Department

Department of Education of Guangdong Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D2MD00298A

Reference30 articles.

1. Vaccine Adjuvants: from 1920 to 2015 and Beyond

2. Key roles of adjuvants in modern vaccines

3. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action

4. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity